ReviewFrontiers in public health2023
Opioid use disorder: current trends and potential treatments.
Review in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Evaluating comparative effect of non-pharmacological interventions adjunctive to opioid agonist therapy for opioid use disorder: A systematic review with network meta-analysis.Addiction (Abingdon, England) · 2026Pooled it
- Trial
- Adults with problematic opioid use released from jail: Mutual help groups and medication support contribute to a greater likelihood of opioid abstinence.Drug and alcohol dependence · 2026Article
- Individualizing Perioperative Analgesia: Patient-Specific Determinants of Postoperative Pain and Opioid-Related Outcomes.Medicina (Kaunas, Lithuania) · 2026Review
- Language, Social Support, and Recovery-Stage Transitions in Opioid Use Disorder on Reddit: Computational Analysis.Journal of medical Internet research · 2026Article
- GEM-GPT Enables Personalized Cell Type-Resolved Therapeutic Design for Systems Pharmacology.bioRxiv : the preprint server for biology · 2026Article
- Emerging Insights into the Distinct Pharmacological Mechanisms of Buprenorphine.Journal of chemical information and modeling · 2026Article
- Can Buprenorphine Be Overdosed? The Ceiling Effect and Its Clinical Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Opioid-Induced Nodding-Not a Nice Nap.Acta scientific neurology · 2026Article
- "This whole thing is relationship medicine": A qualitative analysis of mobile and street-delivered medication for opioid use disorder in King County, Washington, using RE-AIM.Research square · 2026Article
- The Efficacy of Spirulina on Cognitive Function, Psychological and Clinical Indicators in Men Patients Under Methadone Therapy (a Randomized Trial).Food science & nutrition · 2026Article
- Endocannabinoid response to social stress in chronic non-medical prescription opioid users.Psychopharmacology · 2026Article
- The impacts of pricing and reimbursement policies on access to cell and gene therapies across Europe.Journal of community genetics · 2026Review
- Case Report: Delirium and complications resulting from the abuse of compound liquorice tablets.Frontiers in psychiatry · 2026Article
- Methamphetamine-Associated Pulmonary Arterial Hypertension: Impact, Mechanisms, and a Framework for Management.Pulmonary circulation · 2026Review
- Cannabinoid CB1 receptor and mu-opioid receptor interaction: new insights from conditional knockout mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- The use ofFrontiers in cell and developmental biology · 2026Review
- Leveraging pharmacy partnerships and Grant funding to improve access to medications for opioid use disorder.Exploratory research in clinical and social pharmacy · 2025Article
- Review
- Soyasaponin Bb Attenuates Morphine Withdrawal-Induced Anxiety-Like Behaviors in Male Mice by Rescuing GSK-3β/Nrf2 Signaling.Psychiatry investigation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Opioid use disorder (OUD) is a major public health threat, contributing to morbidity and mortality from addiction, overdose, and related medical conditions. Despite our increasing knowledge about the pathophysiology and existing medical treatments of OUD, it has remained a relapsing and remitting disorder for decades, with rising deaths from overdoses, rather than declining. The COVID-19 pandemic has accelerated the increase in overall substance use and interrupted access to treatment. If increased naloxone access, more buprenorphine prescribers, greater access to treatment, enhanced reimbursement, less stigma and various harm reduction strategies were effective for OUD, overdose deaths would not be at an all-time high. Different prevention and treatment approaches are needed to reverse the concerning trend in OUD. This article will review the recent trends and limitations on existing medications for OUD and briefly review novel approaches to treatment that have the potential to be more durable and effective than existing medications. The focus will be on promising interventional treatments, psychedelics, neuroimmune, neutraceutical, and electromagnetic therapies. At different phases of investigation and FDA approval, these novel approaches have the potential to not just reduce overdoses and deaths, but attenuate OUD, as well as address existing comorbid disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.